Portfolio
We say no to far more than we say yes. These are the medical device companies we have backed.
Our portfolio is concentrated by design. We have raised nearly $50M to invest in the companies below.

Auris Health(now Monarch)
Robotic endoluminal platform
Lung cancer detection & bronchoscopy
Turambar LLC · 2017
Uromedica
ProACT, adjustable balloon device
Stress urinary incontinence
Felagund LLC · 2019
Capstan Medical
Robotic transcatheter mitral & tricuspid valve replacement
Structural heart
Telperion Investors LLC · 2022
Telperion Investors II LLC · 2023
Telperion Investors III LLC · 2024
Rivermark Medical
Nitinol stent for BPH
Benign prostatic hyperplasia
Anduril Investors LLC · 2023
Anduril Investors II LLC · 2024
Bright Uro
Sensor-based urodynamics platform
BPH, OAB, SUI, NLUTD diagnostics
Laurelin Investors LLC · 2024
Mendaera
AI-guided robotic injection & telepresence
Interventional radiology & urology
Rivendell Investors LLC · 2024
Verve Medical
Renal pelvic denervation
Resistant hypertension
Olorin Investors LLC · 2025
Spirair
SeptAlign & TurbalAlign: minimally invasive nasal airway
ENT / deviated septum
Sulimo Investors LLC · 2025
HistoSonics
Robotic histotripsy: focused ultrasound tumor destruction
Oncology / interventional radiology
Athelas Investors LLC · 2025
Athelas Investors II LLC · 2026
Realized Outcomes
Two acquisitions to date. Auris Health to Johnson & Johnson (2019) and Uromedica to Coloplast (2026), each from the platform's earliest investment vehicles, Turambar and Felagund.
Each investment is organized as its own dedicated, single-asset vehicle. Vehicles are managed by Telperion Manager LLC or by Athelas Manager LLC, as indicated on each investment. All vehicles are organized as Delaware limited liability companies and offered on a private placement basis to accredited investors only. This site is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Any offer or solicitation will be made only through confidential offering materials and only to persons who, among other requirements, are accredited investors. Any figures shown (including amounts raised) are approximate and presented as of the dates indicated; they are subject to change without notice. Telperion Manager LLC and Athelas Manager LLC are each exempt reporting advisers and are not registered as investment advisers with the U.S. Securities and Exchange Commission. Past investments are not indicative of future results.